{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-26-010507","form_type":"8-K","ticker":"OLMA","cik":"0001750284","company_name":"Olema Pharmaceuticals, Inc.","filed_at":"2026-01-12T23:59:59+00:00","discovered_at":"2026-05-14T18:02:36.071544+00:00","generated_at":"2026-05-16T10:54:33.678006+00:00","sec_items":["2.02","7.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.5,"calibrated_materiality_score":0.5,"confidence":"high","headline":"Olema reports preliminary cash >$500M as of Dec 31, 2025","bullets":["Preliminary unaudited cash, equivalents and marketable securities exceed $500M (subject to year-end close).","No other financial results disclosed; annual 10-K filing pending.","Investor presentation posted on company website as of January 12, 2026.","Cash position provides runway for ongoing breast cancer pipeline development."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-26-010507","json":"https://secwatch.observer/filing/0001193125-26-010507.json","markdown":"https://secwatch.observer/filing/0001193125-26-010507.md","text":"https://secwatch.observer/filing/0001193125-26-010507.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1750284/000119312526010507/0001193125-26-010507-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1750284/000119312526010507/olma-20260112.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-16T10:54:33.678006+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}